CD4 - Grant of ARIPO Patent

RNS Number : 8643A

Omega Diagnostics Group PLC

25 February 2014

 



Omega Diagnostics Group PLC

("Omega" or the "Company")

CD4 - Grant of ARIPO Patent

Omega (AIM: ODX), the medical diagnostics company focused on allergy, food intolerance and infectious disease, announces that it has just been informed by the Burnet Institute that its exclusively licensed CD4 test for monitoring HIV-positive patients has been awarded a Patent in 15 of the African Regional International Property Organisation ("ARIPO") States.  The patent takes effect from 24 July 2013 under number AP 2703.  The grant of this patent widens the protection from territories where patents have already been granted in the US, South Africa and the member states of the African Intellectual Property Organisation ("OAPI") and with patents pending in other territories.

Contacts:

Omega Diagnostics Group PLC	Tel: [phone]
Andrew Shepherd, Chief Executive	www.omegadiagnostics.com
Kieron Harbinson, Group Finance Director
Jag Grewal, Group Sales and Marketing Director
finnCap Ltd	Tel: [phone]
Geoff Nash/Christopher Raggett (Corporate Finance)
Stephen Norcross/Mia Gardner (Corporate Broking)
Walbrook PR Limited	Tel: [phone] or [e-mail]
Paul McManus	Mob: [phone]
Lianne Cawthorne	Mob: [phone]

Information on African Intellectual Property Organisations

The 15 member states of ARIPO where the patent is granted comprise Botswana, Gambia, Ghana, Kenya, Lesotho, Malawi, Mozambique, Namibia, Sierra Leone, Sudan, Swaziland, Tanzania, Uganda, Zambia and Zimbabwe.

The OAPI states are a union of French speaking African countries.

Member states are: Benin, Burkina Faso, Cameroon, the Central African Republic, Chad, Comoro Islands, Congo, Equatorial Guinea, Gabon, Guinea, Guinea-Bissau, Ivory Coast, Mali, Mauritania, Niger, Senegal and Togo.

 

END

 

 

MSCGMGZZGKKGDZM